We further validated these findings in CHLA-20 cells that express the more common R1275Q mutation, suggesting that various ALK mutations respond similarly to the combination in the setting of non-amplified MYCN. These findings suggest that mutant ALK-expressing NB cells with non-amplified MYCN may respond better to an inhibitor that is equally potent against mTOR and PI3K when combined with crizotinib. The gene discussed is ALK; the disease is neuroblastoma.